EUCTR2017-000706-37-DE进行中（未招募）1 期
A Patient and Investigator-blinded, randomized, placebo controlled study of LLG783 in patients with peripheral artery disease (PAD) and intermittent claudication.
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 46
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Clinical evidence of PAD and intermittent claudication. Intermittent claudication, as defined by pain with exertion in either leg
- •On stable medical therapy for PAD and PAD symptoms, which may include statins, aspirin, and antiplatelet medications (as medically indicated) unless individually contraindicated, for at least 4 weeks prior to the screening visit.
- •Vital signs must be within the following ranges:
- •o body temperature between 35.0-37.5°C
- •o systolic blood pressure, 90-159 mm Hg
- •o diastolic blood pressure, 50-99 mm Hg
- •o pulse rate, 50 - 90 bpm
- •Moderately impaired ambulatory function judged by the investigator to be due primarily to PAD and assessed by a maximum walk distance between 50 and 400 meters (inclusive of these values) at the screening 6MWT.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •Pregnant or nursing (lactating) women.
- •Patients who meet any of the following PAD related criteria:
- •o Patients actively attending and participating in a supervised exercise rehabilitation program (patients who have already
- •completed such a program and remain symptomatic may be included).
- •o Patients with any condition other than PAD that limits walking
- •o Known inflammatory disease of the arteries (other than atherosclerosis; e.g. Thromboangiitis obliterans).
- •o Clinical evidence of critical limb ischemia including new or non-healing ulcers (felt secondary to critical limb ischemia), new or
- •recent onset of resting pain in the lower extremities particularly at
- •night (felt secondary to critical limb ischemia) and/or gangrene of
- •the lower extremities (Fontaine stage III-IV) .
- •Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 150 days after stopping of investigational drug
- •Any of the following concomitant cardiovascular or metabolic conditions or diseases:
- •o Myocardial infarction within 6 months of screening.
- •o Stroke within 6 months of screening.
- •o History of clinically significant ventricular arrhythmias, according to
- •the discretion of the investigator, within 6 months of screening.
- •o Significant ECG abnormalities, according to the discretion of the
- •investigator, at screening.
- •o History of sustained and clinically significant supraventricular
- •arrhythmias (e. g. associated with hemodynamic compromise)
- •within 6 months of screening.
- •o Chronic heart failure New York Heart Association Class III or IV.
- •o Known presence of aortic aneurysm > 5 cm.
- •o Uncontrolled diabetes as defined by a random fasting glucose level
- •of 13 mmol/L or 240 mg/dL or a HbA1c greater than 9% as measured at screening. Diabetes should be treated as appropriate
- •during the study.
研究者
相似试验
进行中（未招募）
1 期
Safety, tolerability and efficacy study of CLL442 in patients with Cutaneous Squamous Cell Carcinoma in situ (SCCis).EUCTR2017-003495-31-BEovartis Pharma AG40
进行中（未招募）
1 期
Safety, tolerability, pharmacokinetics and efficacy of LMB763 in patients with non-alcoholic steatohepatitis (NASH)non-alcoholic steatohepatitis (NASH)MedDRA version: 20.1Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2016-002833-31-GBovartis Pharma Services AG121
进行中（未招募）
1 期
Study of safety and efficacy of CFZ533 in type 1 diabetes pediatric and young adult subjects.EUCTR2018-004553-25-ITOVARTIS PHARMA AG102
进行中（未招募）
1 期
Study of safety and efficacy of CFZ533 in type 1 diabetes pediatric and young adult subjectsTreatment of subjects with type 1 diabetes mellitus with residual beta cell function (RBCF), with the goal of preserving RBCFMedDRA version: 21.1Level: PTClassification code 10067584Term: Type 1 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2018-004553-25-BEovartis Pharma AG44
进行中（未招募）
1 期
Study of safety and efficacy of CFZ533 in type 1 diabetes pediatric and young adult subjectsTreatment of subjects with type 1 diabetes mellitus with residual beta cell function (RBCF), with the goal of preserving RBCFMedDRA version: 21.1Level: PTClassification code 10067584Term: Type 1 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2018-004553-25-SIovartis Pharma AG44